Featured Research
This page features research conducted by RAND Health research staff that has been published in a scholarly journal.Drug Licenses: A New Model For Pharmaceutical Pricing
Goldman DP, Jena AB, Philipson T, Sun E. Health Affairs, 27, no. 1 (2008): 122-129.
Read article (may require registration or payment on Health Affairs website)
Abstract
High drug prices are a major barrier to patients’ access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation. We propose a drug-licensing model for health care, which has the promise of increasing drug use without altering patients’ out-of-pocket spending, health plans’ costs, or drug companies’ profits. In such a model, people would purchase annual drug licenses that would guarantee unfettered access to a clinically optimal number of prescriptions over the course of a year. Using the example of statins, we illustrate how such a model could be implemented.
Top